Kaike

Quick links to important sections

Kaike

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kaike

Quick Facts

Property Description
Active ingredient Bepridil hydrochloride
Form Oral tablet
Pharmacological class Calcium Channel Blocker (CCB)
Common use Antianginal agent (used to ease heart-related chest pain)
Origin Synthetic compound
Prescription Status Prescription Drug (Rx)

What is Kaike and What is its Composition?

Kaike is the trade name for a prescription-only medication used to manage chronic heart conditions. Its active component is the chemical substance bepridil hydrochloride (also known simply as bepridil). This substance is categorized as a synthetic compound, meaning it is produced in a laboratory and is not naturally sourced. The medication is manufactured as a single-component drug for oral administration in the form of a tablet.

Pharmacological Type and Differentiation

Bepridil belongs to the core pharmacological class known as Calcium Channel Blockers (CCBs). However, bepridil is differentiated from many other CCBs because it is considered a non-selective channel blocker. This means it is recognized for affecting multiple ion channels in the heart—including calcium, sodium, and potassium currents—which provides a broader, multi-faceted action on the cardiovascular system.

General Therapeutic Purpose

The general purpose of Kaike (bepridil) is to ease the workload on the heart and increase its efficiency. This is achieved through its primary role as an antianginal agent. By helping coronary blood vessels relax and reducing the heart muscle’s demand for oxygen, the drug supports more effective blood flow. This action has been clinically recognized for providing significant anti-anginal activity.

What side effects are possible with Kaike?

Possible Side Effects and Safety Information

Kaike, a representative Janus Kinase (JAK) inhibitor, is associated with a specific set of serious adverse reactions that are prominently noted in official regulatory documents from authorities like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Serious and clinically significant risks documented include:

  • Major Adverse Cardiovascular Events (MACE): This includes an increased risk of heart attack, stroke, and cardiovascular death.
  • Malignancies: There is an increased risk of developing certain cancers, including lymphoma and lung cancer. Periodic skin examinations are recommended for patients, particularly those at higher risk for skin cancer.
  • Serious Infections: An increased risk of serious infections, including opportunistic infections like tuberculosis and herpes zoster (shingles), has been observed.
  • Thromboembolic Events: This includes an elevated risk of blood clots in the deep veins (Deep Vein Thrombosis, DVT) and lungs (Pulmonary Embolism, PE).
  • Death: An increased risk of death from any cause has been noted in clinical safety trials compared to certain other treatment classes.
Population-Specific Safety Considerations
Reserved Use: Treatment with this drug class is reserved for patients who have had an inadequate response or intolerance to one or more TNF blockers.
High-Risk Groups: The drug should only be used if no suitable alternative treatments are available for patients aged 65 years or older, those who are current or past long-time smokers, or those with a history of atherosclerotic cardiovascular disease or other cardiovascular risk factors.
Dose-Related Patterns: Increased risks of blood clots and death were observed with both higher and approved lower doses of the reference compound in a major safety trial.

Regulatory agencies require that these risks be highlighted in the most prominent warnings (e.g., the FDA Boxed Warning). Caution is advised, and dose adjustments may be necessary for patients with certain pre-existing conditions or risk factors related to these adverse events.

Overdose and Emergency Response

The regulatory information for Kaike (bepridil) overdose focuses on the risk of severe, life-threatening cardiovascular effects that necessitate immediate professional medical intervention.

Overdose Scope Official Regulatory Findings
Documented Manifestations Overdose presents as exaggerated adverse reactions, including clinically significant hypotension (low blood pressure) and high-degree AV block (conduction disturbance).
Severe Outcomes The most serious documented risks are ventricular arrhythmias, such as ventricular tachycardia and Torsades de Pointes, which can lead to cardiac arrest.
Emergency Actions Immediate medical attention must be sought for any known or suspected overdose. Close observation in a cardiac care facility for a minimum of 48 hours is specified by the regulatory labeling.
Management Overview Regulatory Basis
Antidote Status No specific antidote is known for bepridil overdose.
Required Treatment Management consists of symptomatic and supportive treatment. Procedures such as gastric lavage, use of activated charcoal, and continuous cardiac monitoring are officially described steps.

The official overdose profile requires immediate and definitive action due to the high risk of severe cardiac rhythm disturbances. The mandatory course of action is to contact emergency medical services immediately upon suspicion of overdose, as the documented severity of manifestations demands advanced supportive measures and specialized hospital observation.

Therapeutic Uses of Kaike

What Kaike Treats: Main Uses and Benefits

Kaike is prescribed for the long-term management of specific chronic heart conditions, focusing on easing symptom frequency and supporting functional stability in daily life. Bepridil has recognized anti-anginal activity and is used for therapeutic purposes associated with the cardiovascular system.

Kaike is primarily considered relevant for managing chronic stable angina pectoris, which involves recurring chest discomfort or pressure, and is also used for addressing certain specific abnormal heart rhythms like sustained atrial fibrillation.

Easing Discomfort and Supporting Stability

This medication is commonly used to help with symptoms related to physical discomfort and tension in the chest. It provides support that helps ease the overall symptom burden, particularly when patients experience discomfort that interferes with daily functioning and creates noticeable physiological strain.

“This approach to symptom relief may help patients cope more steadily with difficult episodes and contribute to improved day-to-day comfort.”

Kaike is often employed in clinical settings where patients have required an alternative agent due to an insufficient response to or intolerance of other treatments, making it a relevant option for managing conditions characterized by periods of heightened symptoms.

Quick Fact: Relief for Angina Pectoris
Therapeutic Aim Easing the frequency and intensity of recurring chest discomfort.
Context Used when patients have an insufficient response to initial antianginal treatments.
Patient Benefit Supports maintenance of functional stability during physical effort.

Eligibility and Restrictions for Use

Eligibility Scope

Kaike (bepridil) is reserved for adult patients who have not responded optimally to, or are intolerant of, other antianginal medication. Official regulatory documents establish clear restrictions based on heart health, organ function, and age.

Eligibility Status Population/Condition Regulatory Wording
Contraindicated History of serious ventricular arrhythmias or QTc interval >0.44 seconds Absolute Prohibition
Contraindicated Severe left ventricular dysfunction (e.g., NYHA Class III/IV heart failure) Absolute Prohibition
Contraindicated Hypersensitivity, or certain conduction issues (e.g., Sick Sinus Syndrome, 2nd/3rd degree AV block without a pacemaker) Absolute Prohibition
Not Recommended Use in children and adolescents under 18 years of age Safety and efficacy have not been established
Not Recommended Patients with moderate or severe liver disease or within three months of a heart attack Conditional Exclusion
Restricted Use Pregnancy (FDA Category C) and Lactation Use only if benefit justifies risk; may require discontinuing nursing
Restricted Use Patients with serious renal disorders or hepatic impairment Use with caution, due to high metabolism and lack of study data

Electrolyte imbalances, specifically low potassium or magnesium, must be corrected prior to initiation of therapy. The medicine may be used in older adults, but regulatory bodies advise caution due to increased drug levels in this population.

What should I know about interactions with other medicines?

Kaike (bepridil) is associated with officially documented interactions primarily linked to its cardiovascular effects and hepatic clearance.

Formal Contraindicated Combinations

Co-administration of Kaike is strictly prohibited with all medicinal products that are known to prolong the QT interval, including Class IA and Class III Antiarrhythmic Drugs. This restriction is mandated by regulatory agencies due to the significant, additive risk of developing life-threatening ventricular arrhythmias.

Pharmacodynamic Interactions

Product Class Official Interaction Pattern/Outcome
Cardiodepressant Agents (e.g., Beta-blockers) Use may result in an additive negative inotropic effect, potentially leading to excessive bradycardia or heart failure.
Potassium-Wasting Diuretics May induce hypokalemia, which is officially recognized as substantially increasing the susceptibility to bepridil-induced arrhythmias.

Metabolic and Exposure Alterations

  • CYP450 3A4 Inhibitors: Bepridil is metabolized by the CYP3A4 enzyme; co-administration with inhibitors may cause a regulatory-documented increase in the drug's plasma concentration, raising the risk of concentration-dependent effects.
  • Grapefruit Juice: Consumption may increase bepridil plasma exposure due to inhibition of intestinal CYP3A4-mediated metabolism.

Population-Specific Note

Interaction severity may be heightened in patients with severe hepatic impairment due to the drug's prolonged half-life and risk of accumulation, a consideration noted in official labeling.

This structure exclusively outlines the documented pharmacological and metabolic constraints that govern its use, as defined by government regulatory documents.

Mechanism of Action

️ Modulation of Ion Channel Flow and Electrical Stability

This mechanism involves blocking multiple electrical gatekeepers, including L-type Calcium ( Ca^2+), Sodium ( Na^+), and Potassium ( K^+) channels, within heart muscle cells and blood vessels. By modulating the movement of these ions, the molecule influences the cell’s electrophysiological excitability. This interference with the repolarization phase by blocking K^+ currents prolongs the Action Potential Duration (APD), resulting in the prolongation of the electrical recovery period.

️ Dual Action on Myocardial Contractility

The drug affects the heart’s pumping force through two opposing but balanced actions. Blocking Ca^2+ influx initiates negative inotropy, while the molecule also acts as a Ca^2+-sensitizer, increasing the responsiveness of the contractile protein Troponin C ( cTnC) to the available intracellular Ca^2+. This unique balancing mechanism produces a net decrease in myocardial force generation.

Relaxation of Vascular Smooth Muscle

This mechanism focuses on decreasing systemic and coronary vascular resistance. By inhibiting the action of Ca^2+ and acting as an antagonist of Calmodulin ( CaM) in the walls of blood vessels, the drug suppresses the signaling pathway responsible for muscle tightening. The resulting vasodilation (widening of the vessels) decreases vascular resistance and enhances coronary perfusion.

Dosage and Administration Information

Kaike is administered strictly via the oral route and is prescribed for long-term management of chronic conditions. The medication is taken using the film-coated tablet form, available in strengths including 200 mg, 300 mg, and 400 mg.

Dosing and Frequency

The established standard regimen for adults begins with an initial dose of 200 mg taken once daily. The medicine is designed for a once-daily intake pattern. The standard maintenance dose typically falls within the range of 300 mg to 400 mg daily. The maximum authorized daily dose for bepridil is 400 mg. Dosage adjustments, such as increasing from the initial amount, are not typically made until a minimum of 10 days of therapy has passed to allow the drug to reach stable levels in the body.

Administration Conditions

Kaike tablets can be taken with or without food, as absorption is not significantly affected by meals. If the patient experiences nausea, the official administration guidance suggests the dose may be taken at meals or at bedtime. For older adults, the initial starting dose is the same as the standard adult dose.

Procedural Context

These official instructions establish a fixed, once-daily procedural framework for using the drug as a long-term maintenance treatment. The mandatory 10-day delay for any dose titration is a key procedural constraint that structures the overall use of the medication.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy and Outcomes Research

Core Findings from Pivotal Trials

The primary research question for the pivotal trials investigated whether lung function was affected in participants with a specific respiratory condition. A key Phase 3 trial reported a change in symptoms over a specified period when compared to a placebo group. The study reports its findings and is one factor contributing to the body of evidence being examined.

  • Symptom Reporting: Participants who were administered the drug reported symptom changes. Researchers examined differences in quality of life metrics between the active drug group and the control group over a 12-week period.

  • Combination Research: Research has also explored the potential for combined use to impact short-term relief and long-term control in specific participant populations.

Data on Specific Subgroups

Pediatric Population Studies specifically evaluated the drug's profile in pediatric participants (aged 6 to 17). This research specifically investigated reported changes in pain and inflammation and compared these results to those seen in adult trials. The evidence in this age group remains limited due to the small number of trials conducted.

Geriatric Population This research examined the drug's profile in older participants (aged 65 and above). The study protocol mandated a specific administration schedule for the medication.

Severity Subgroups Studies have evaluated the drug's profile in participants with mild to moderate cases. Research participants did not include individuals diagnosed with severe asthma. The available research does not include data for this specific subgroup. This research is part of ongoing efforts to study various treatment approaches.

  • Note: All participants in the included studies had received a confirmed diagnosis of the condition being studied.

Research on Adverse Events

Initial studies evaluated the incidence of adverse events (side effects) and recorded the frequency and severity of reported side effects. The most frequently reported adverse events in these studies were headache and fatigue. Ongoing research efforts continue to monitor participant health over extended time periods.

Frequently Asked Questions (FAQ)

Common questions about Kaike (FAQ)


Q: How quickly does Kaike start to work after taking it?

Kaike has a long terminal half-life, meaning it takes a long time for the body to process it. Because of this, it can take at least 10 days for the medication to reach steady, stable levels in the body. This is why official administration guidance suggests a delay before considering any changes to the amount being taken.


Q: What's the difference between Kaike and other similar medicines?

Kaike is officially classified as a Calcium Channel Blocker (CCB). However, unlike some other drugs in this class, official product information describes it as a non-selective channel blocker. This means it is recognized for affecting multiple electrical pathways in the heart, specifically calcium, sodium, and potassium currents.


Q: Is Kaike a type of pain reliever?

Kaike is formally known as an antianginal agent. Its main purpose is to ease the workload on the heart and improve blood flow, which in turn helps to manage and relieve heart-related chest pain, known as angina pectoris. Its approved therapeutic purpose is as an antianginal agent, and it is not formally classified or approved as a general painkiller.


Q: Does Kaike affect blood pressure?

The mechanism of action for Kaike involves causing vasodilation, which is the widening of blood vessels, leading to a decrease in vascular resistance. While the drug is not primarily intended to treat high blood pressure, this mechanism may affect overall blood pressure. Hypotension (low blood pressure) is also listed in official documentation as a reported adverse reaction.


Q: Is there a generic version of Kaike available?

The active ingredient in Kaike is bepridil hydrochloride. Generic versions are medications that contain this exact same active ingredient and meet the same regulatory standards for quality and effectiveness as the brand-name product.


Q: Is there a different name for Kaike in other countries?

Kaike is a specific trade name given to the medication by the manufacturer. While this trade name can vary between countries, the core active ingredient remains the same globally: bepridil hydrochloride.


Q: What should I tell my doctor before starting Kaike?

Official guidelines emphasize sharing a complete medical history, especially any previous heart rhythm problems, QTc interval abnormalities, or severe left ventricular dysfunction (like advanced heart failure). Regulatory documents indicate that patients are typically required to inform their provider of any liver or kidney disease and any known electrolyte imbalances, such as low potassium or magnesium, before starting treatment.


Q: Are there any known long-term effects of using Kaike?

The medication is intended for the long-term management of chronic conditions. Regulatory safety data, particularly for this drug class, highlights documented serious risks associated with extended use. These include major cardiovascular events, malignancies (cancers), serious infections, and blood clots.


Q: Is Kaike generally well-tolerated?

Clinical trial data provides specific incidence rates for adverse reactions. The most frequently reported non-serious side effects often include symptoms like headache and fatigue. However, regulatory warnings also highlight the potential for serious risks, which should be considered.


Q: Why does the official leaflet mention a risk of a certain rare side effect?

Government drug regulatory agencies, such as the FDA and EMA, require complete transparency regarding drug safety. This means that all documented adverse events and risks, including those observed only rarely in studies or post-market surveillance, must be included in the official patient information leaflets.


Q: How does the action of Kaike differ from an older class of drugs?

Kaike is chemically distinct from older antianginal drug classes like nitrates or beta-blockers. Its action is unique because it is a non-selective channel blocker, meaning it affects more than one type of electrical gatekeeper (calcium, sodium, and potassium) in the heart and blood vessels.


Q: Is Kaike considered a strong medicine?

The official product information does not use subjective terms like 'strong.' Instead, regulatory guidance states that Kaike is reserved for adult patients who have not responded optimally to, or who cannot tolerate, other existing antianginal medicines.


Q: Is it normal to feel a bit dizzy when first taking Kaike?

Official documentation lists dizziness as a reported adverse reaction associated with the use of the drug. If a patient experiences this or any other effect, seeking guidance from a healthcare professional is generally advised.


Q: What happens if I miss a dose of Kaike?

Instructions for a missed dose are typically contained within the drug's prescribing information. For once-daily (QD) medications, standard guidelines usually specify taking the missed dose if remembered shortly, or skipping it entirely if the next dose is near, in order to resume the normal schedule. Double dosing is generally specified as an action to be avoided.


Q: Can Kaike interact with common over-the-counter supplements?

Kaike is known to interact with substances that inhibit the CYP3A4 enzyme in the body, which can increase the drug's concentration. Since some over-the-counter supplements and herbal products may affect this enzyme, for transparency, patients are typically required to disclose all supplements they are taking to their healthcare provider or pharmacist.


Q: Are there any known interactions between Kaike and herbal teas?

Official documentation notes an interaction with Grapefruit Juice, which affects the CYP3A4 metabolic enzyme. Although other specific herbal teas are not listed, given the potential for interaction with the CYP3A4 pathway, discussing the use of herbal products with a healthcare provider is generally recommended.


Q: What do I do if I think I'm experiencing a side effect from Kaike?

If a patient suspects an adverse reaction, they may seek guidance from a healthcare professional or, if symptoms are severe, seek emergency medical care. Adverse events can also be reported directly to the relevant governmental regulatory agency.


Q: Is Kaike addictive or habit-forming?

Kaike (bepridil) is not listed or classified as a controlled substance by regulatory bodies such as the U.S. Drug Enforcement Administration (DEA). The drug is not known to be addictive or habit-forming.


Q: How long does Kaike stay in your system?

The medication has a long terminal half-life of approximately 42 hours. Based on this pharmacokinetic data, it generally takes several days for the drug to be fully eliminated and undetectable in the body.


Q: Can I take Kaike if I am already taking an antibiotic?

Caution is required because some antibiotics are known to inhibit the CYP3A4 metabolic enzyme or can prolong the QT interval, which are both classified as potential contraindications or significant interaction risks with this medication. In accordance with regulatory guidance, patients are required to disclose all current medications, including antibiotics, to their prescribing doctor or pharmacist before commencing therapy.


Q: Does Kaike affect mental focus or clarity?

Adverse events related to the nervous system, such as dizziness and nervousness, have been reported in clinical studies. If patients experience these particular side effects, it may potentially impact their ability to maintain focus or clarity.


Q: How is Kaike usually packaged or sold?

Kaike is supplied as film-coated tablets in its various authorized strengths. The containers are required by regulation to feature safeguards such as child-resistant and tamper-evident closures to ensure product integrity and safety.


Q: Can Kaike be crushed or chewed if someone has trouble swallowing pills?

The medication is supplied as a film-coated tablet intended for oral administration. The regulatory labeling does not provide instructions or authorization for crushing, breaking, or chewing the film-coated tablet. Any alteration of the approved dosage form is not addressed in official documents.


Q: What are the signs of a severe allergic reaction to Kaike?

Official documents note that signs of a severe allergic reaction may include difficulty breathing, swelling of the face, throat, or tongue (angioedema), or hives. Severe skin reactions have also been documented within the drug class.


Q: Does Kaike have a specific warning about driving or operating machinery?

The drug is associated with nervous system side effects, including dizziness and fatigue. Given the potential for effects on the central nervous system, official product information typically notes that caution may be necessary when driving or operating complex machinery.


Q: Are there any specific lifestyle changes recommended while taking Kaike?

Official regulatory documents emphasize that patients must have any electrolyte imbalances (like low potassium or magnesium) corrected before starting therapy. Furthermore, the label mandates avoiding certain foods or beverages, specifically grapefruit juice, due to known drug interaction risks.


Q: Can Kaike be taken at the same time as cold or flu medicine?

Cold and flu remedies may contain ingredients that can potentially interact with Kaike by prolonging the QTc interval or affecting metabolic enzymes. Patients are typically required to consult with their pharmacist or doctor before combining Kaike with any cold or flu remedy, as this is necessary to address potential safety concerns.


Q: Is Kaike considered an anti-inflammatory drug?

Kaike is formally classified by regulatory agencies as a Calcium Channel Blocker (CCB) and its approved therapeutic use is as an antianginal agent. It is not formally classified or approved for use as an anti-inflammatory drug.


Q: Is the effect of Kaike permanent or does it stop when you stop taking it?

The effect of the drug is based on reversible changes in the electrical flow within heart cells and is not permanent. Its effects gradually stop as the drug is cleared from the body, which takes several days due to its long half-life.


Q: What information should I look for in the official Kaike leaflet?

The official patient information leaflet contains all essential details required by government regulators. This includes the approved uses, a complete list of known side effects (both common and serious), all potential interactions, and necessary dosing and storage instructions.

How should Kaike be stored and disposed of?

How to Store and Dispose of Kaike? (Official Regulatory Information)

This section outlines the general storage, handling, and disposal requirements for prescription pharmaceuticals, based on regulatory standards from government authorities (e.g., FDA/DEA/EPA), as Kaike-specific labeling was not publicly available.

Mandatory Storage and Handling

Prescription medications must be stored at the temperature specified on the labeling, typically at Controlled Room Temperature. Storage facilities must be secure, free from infestation, and control for humidity and light. Containers must feature child-resistant and tamper-evident closures to prevent unauthorized access and protect the product's integrity.

Disposal Requirements

  • General Rule: Unwanted or expired medication must be disposed of in accordance with federal, state, and local laws. Drugs that are damaged or outdated must first be quarantined.
  • Controlled Substances: If classified as a controlled substance, disposal must adhere to specific rules, often involving methods that render the substance unrecoverable.
  • Environmental: Disposal must prevent environmental contamination, and flushing is generally prohibited unless explicitly permitted by the drug's label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kaike found in:

A-Z Index: